HK66293A - Human granulocyte colony stimulating factor - Google Patents

Human granulocyte colony stimulating factor

Info

Publication number
HK66293A
HK66293A HK662/93A HK66293A HK66293A HK 66293 A HK66293 A HK 66293A HK 662/93 A HK662/93 A HK 662/93A HK 66293 A HK66293 A HK 66293A HK 66293 A HK66293 A HK 66293A
Authority
HK
Hong Kong
Prior art keywords
colony stimulating
granulocyte colony
stimulating factor
human granulocyte
csf
Prior art date
Application number
HK662/93A
Other languages
English (en)
Inventor
Masayoshi Ono
Hitoshi Nomura
Masahiko Tamura
Masahiko Matsumoto
Tatsumi Yamazaki
Osami Yamamoto
Yuichi Hirata
Yasuo Sekimori
Masayuki Tsuchiya
Shigekazu Nagata
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP60023777A external-priority patent/JPH0615477B2/ja
Priority claimed from JP60269455A external-priority patent/JPS62129298A/ja
Priority claimed from JP60270838A external-priority patent/JPH06102021B2/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of HK66293A publication Critical patent/HK66293A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK662/93A 1985-02-08 1993-07-08 Human granulocyte colony stimulating factor HK66293A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP60023777A JPH0615477B2 (ja) 1985-02-08 1985-02-08 感染防禦剤
JP20606685 1985-09-17
JP20963885 1985-09-20
JP26945685 1985-12-02
JP60269455A JPS62129298A (ja) 1985-12-02 1985-12-02 新規ポリペプチド
JP27083985 1985-12-03
JP60270838A JPH06102021B2 (ja) 1985-12-03 1985-12-03 新規なポリペプチド
PCT/JP1986/000052 WO1986004605A1 (fr) 1985-02-08 1986-02-07 Facteur de stimulation de colonies de granulocytes humains

Publications (1)

Publication Number Publication Date
HK66293A true HK66293A (en) 1993-07-16

Family

ID=27564006

Family Applications (1)

Application Number Title Priority Date Filing Date
HK662/93A HK66293A (en) 1985-02-08 1993-07-08 Human granulocyte colony stimulating factor

Country Status (6)

Country Link
EP (1) EP0215126B1 (fr)
AT (1) ATE65798T1 (fr)
BG (1) BG61925B2 (fr)
DE (1) DE3680613D1 (fr)
HK (1) HK66293A (fr)
WO (1) WO1986004605A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
EP0396158A1 (fr) * 1985-08-23 1990-11-07 Kirin-Amgen, Inc. Production du facteur de stimulation de colonies de granulocytes pluriactifs
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
DE3681551D1 (de) * 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
ATE65403T1 (de) * 1986-01-22 1991-08-15 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
CA1297005C (fr) * 1986-01-22 1992-03-10 Masahiko Tamura Agent pharmaceutique de traitement de la leucemie myeloide
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
EP0256843A1 (fr) * 1986-08-11 1988-02-24 Cetus Corporation Expression de G-CSF et des mutéines de celui-ci et leur utilisation
JP2583770B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
NO176799C (no) * 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
AU632460B2 (en) * 1987-07-16 1993-01-07 Schering Corporation Purification of gm-csf
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
GB2213821B (en) * 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
CA2006596C (fr) * 1988-12-22 2000-09-05 Rika Ishikawa G-csf modifie chimiquement
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
WO1991005798A1 (fr) * 1989-10-10 1991-05-02 Amgen Inc. Compositions et procedes de traitement ou de prevention d'infections chez les animaux canins et felins
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
CA2142453A1 (fr) * 1992-09-09 1994-03-17 Tomio Morino Nk175203, nouvelle substance physiologiquement active; methode de preparation et utilisation en pharmacie
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
WO2004020462A1 (fr) 2002-08-27 2004-03-11 Fujii, Nobutaka Antagoniste de cxcr4 et son utilisation
JP5137821B2 (ja) 2005-06-01 2013-02-06 マキシジェン， インコーポレイテッド Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
EP3011961B1 (fr) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 pour la mobilisation des cellules hématopoiétiques progénitrices en vue d'une transplantation
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
RU2563536C2 (ru) * 2008-10-02 2015-09-20 Октафарма Аг, Способ получения рекомбинантного человеческого g-csf
WO2010092571A2 (fr) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Peptides courts dérivés de bêta-défensine
JP5715622B2 (ja) 2009-06-14 2015-05-07 バイオカイン セラピューティックス リミテッド 血小板レベルを増大させるためのペプチド療法
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2841084B1 (fr) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Peptide antagoniste de cxcr4 et son utilisation pour le traitment de tumeurs pulmonaires
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54140789A (en) * 1978-04-22 1979-11-01 Jitsuken Doubutsu Chuo Kenkiyu Culturing of colony stimulating factor producing tumor cell
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
JPS5978122A (ja) * 1982-10-27 1984-05-04 Ajinomoto Co Inc コロニ−刺激因子の製造法
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor

Also Published As

Publication number Publication date
BG61925B2 (bg) 1998-09-30
EP0215126A4 (fr) 1987-10-05
DE3680613D1 (de) 1991-09-05
EP0215126B1 (fr) 1991-07-31
EP0215126A1 (fr) 1987-03-25
WO1986004605A1 (fr) 1986-08-14
ATE65798T1 (de) 1991-08-15

Similar Documents

Publication Publication Date Title
HK66293A (en) Human granulocyte colony stimulating factor
HK65593A (en) Human granulocyte colony stimulating factor
ES8307297A1 (es) Proceso para la produccion microbiana de interferon fibro- blasto humano
ATA392082A (de) Verfahren und vorrichtung zum handhaben von gegenstaenden mittels kontinuierlich bewegter arbeitsmittel
IL87025A0 (en) Recombinant fibroblast growth factor analogs,their production,dna sequences encoding therefor and recombinant vectors and host cells containing said dna sequences
EP0183350A3 (en) Dna endcoding human colony stimulating factor, peptide encoded thereby,vectors and transformed hosts containing such dna, and the production of all thereof
ES8600783A1 (es) Procedimiento para la preparacion de la hormona polipeptidica factor de crecimiento de nervios de humano.
MD430C2 (ro) Procedeu de obţinere a interferonelor leucocitare umane
AU5233686A (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
AU596997C (en) Pharmaceutical composition for the treatment of leukopenia
SE8101005L (sv) Mikrobiologiskt framstelld polypeptid med samma aminosyrasekvens som hos humant interferon, dna och plasmider, som koderar for denna sekvens, mikroorganismer, som innehaller dessa genetiska informationer och forfaran...
ES8500327A1 (es) Procedimiento para producir polipeptido
AU637139B2 (en) Gm-csf protein, its derivatives, the preparation of proteins of this type, and their use
EP0835661A3 (fr) L'interferon-beta 2A humain,son utilisation comme médicament
JPS6485098A (en) Glycoprotein and production thereof
MY103542A (en) Expression vectors for the production of human granulocyte macrophage colony stimulating factor in a mammalian cell host
ES2056753A6 (es) Un procedimiento para la produccion de un polipeptido que tiene actividad de factor quemotactico de monocitos humanos.
ES2002164A6 (es) Un metodo para producir un polipeptido o una gicoproteina que tiene una actividad de factor estimulante de colonias de granulocitos humanos.
SE8605459D0 (sv) Novel cell growth regulatory factor
EP0165759A3 (fr) Promoteurs mammifères utiles pour l'expression dans des levures
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
DE3853590D1 (de) Rinder granulocyt-makrophagenkolonie stimulierender faktor.
JPS6485095A (en) Novel physiologically active polypeptide
JPS6485094A (en) Novel physiologically active polypeptide

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20060206